US · Healthcare · Biotechnology
EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.
Analysts rate Oncolytics Biotech Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.24.
| Fund | Stake |
|---|---|
| Marshall Wace Asset Management Ltd | 0.67% |
| Renaissance Technologies Corp | 0.56% |
| Sandbox Financial Partners, LLC | 0.31% |
| SEEDS INVESTOR LLC | 0.20% |
| International Assets Investment Management, LLC | 0.16% |
| Connective Capital Management LLC | 0.15% |
| Tocqueville Asset Management L.P. | 0.12% |
| Everhart Financial Group, Inc. | 0.11% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oncolytics Biotech Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.